Painful diabetic peripheral neuropathy: real-world comparison between topical treatment with lidocaine 700 mg medicated plaster and oral treatments

BMJ Open Diabetes Res Care. 2022 Nov;10(6):e003062. doi: 10.1136/bmjdrc-2022-003062.

Abstract

Introduction: Painful diabetic peripheral neuropathy (PDPN), a common complication of diabetes mellitus, is challenging to treat. Efficacy and tolerability of the topical lidocaine 700 mg medicated plaster (LMP) and well-established first-line oral medications (OM) were compared in refractory PDPN patients.

Research design and methods: This is a subgroup analysis of a non-interventional, retrospective 24-week cohort study using anonymized routine medical care data from the German Pain eRegistry. Propensity score matching provided 732 datasets per treatment group. Primary effectiveness endpoint was the absolute change in average 24-hour Pain Intensity Index (0-100 mm) from baseline after 4, 12 and 24 weeks of treatment and over the entire treatment period.

Results: The majority of this multimorbid and polymedicated study population of patients with PDPN had suffered pain for more than a year and presented with a high pain burden despite a median of seven previous analgesic medications. LMP treatment resulted in significant reductions in pain intensity and improvements in daily functioning already after 4 treatment weeks. Effectiveness was maintained over the treatment period even when concomitant analgesics were reduced or discontinued and quality of life improved. Mean change in the primary effectiveness parameter over the 24-week treatment period was -30.2 mm (SE 0.38) and -17.0 mm (SE 0.51) in the LMP and OM groups, respectively. Improvements in all effectiveness parameters were significantly greater under LMP than under OM treatment (p<0.001). Significantly fewer patients under LMP than OM experienced drug-related adverse events (DRAEs; 9.6% vs 61.6%, p<0.001) and discontinued treatment due to DRAEs (4.4% vs 35.8%, p<0.001).

Conclusions: LMP was effective and well tolerated in routine clinical care of patients with PDPN. The more favorable benefit/risk profile and greater reduction in intake of concomitant analgesics compared with OM suggest LMP as a useful treatment option for PDPN.

Trial registration number: EUPAS 32826.

Keywords: Chronic Pain; Diabetes Complications; Diabetic Neuropathies; Patient Reported Outcome Measures.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / adverse effects
  • Analgesics / therapeutic use
  • Cohort Studies
  • Diabetes Mellitus* / drug therapy
  • Diabetic Neuropathies* / drug therapy
  • Humans
  • Lidocaine / adverse effects
  • Lidocaine / therapeutic use
  • Neuralgia, Postherpetic* / chemically induced
  • Neuralgia, Postherpetic* / complications
  • Neuralgia, Postherpetic* / drug therapy
  • Quality of Life
  • Retrospective Studies

Substances

  • Lidocaine
  • Analgesics